Evidence map›Paper›PMID 30410490›Full record

ReviewFrontiers in immunology2018

Role of Osteocytes in Myeloma Bone Disease: Anti-sclerostin Antibody as New Therapeutic Strategy.

Denise Toscani, Marina Bolzoni, Marzia Ferretti, Carla Palumbo, Nicola Giuliani

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 44 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Sclerostin: From Molecule to Clinical Biomarker.International journal of molecular sciences · 2022
    Review
  13. Pathogenesis and Treatment of Myeloma-Related Bone Disease.International journal of molecular sciences · 2022
    Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. The Osteocyte: From "Prisoner" to "Orchestrator".Journal of functional morphology and kinesiology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Denise ToscaniDepartment Medicine and Surgery, University of Parma, Parma, Italy.
Marina BolzoniDepartment Medicine and Surgery, University of Parma, Parma, Italy.
Marzia FerrettiDepartment of Biomedical, Metabolic and Neural Sciences, Human Morphology Section, University of Modena and Reggio Emilia, Modena, Italy.
Carla PalumboDepartment of Biomedical, Metabolic and Neural Sciences, Human Morphology Section, University of Modena and Reggio Emilia, Modena, Italy.
Nicola GiulianiDepartment Medicine and Surgery, University of Parma, Parma, Italy.
University of Parma · ITUniversity of Modena and Reggio Emilia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteocytes are terminally differentiated cells of the osteoblast lineage. They are involved in the regulation of bone remodeling by increasing osteoclast formation or decreasing bone formation by the secretion of the osteoblast inhibitor sclerostin. Monoclonal antibody anti-sclerostin, Romosozumab, has been developed and tested in clinical trials in patients with osteoporosis. In the last years, the role of osteocytes in the development of osteolytic bone lesions that occurs in multiple myeloma, have been underlined. Myeloma cells increase osteocyte death through the up-regulation of both apoptosis and autophagy that, in turn, triggers osteoclast formation, and activity. When compared to healthy controls, myeloma patients with bone disease have higher osteocyte cell death, but the treatment with proteasome inhibitor bortezomib has been shown to maintain osteocyte viability. In preclinical mouse models of multiple myeloma, treatment with blocking anti-sclerostin antibody increased osteoblast numbers and bone formation rate reducing osteolytic bone lesions. Moreover, the combination of anti-sclerostin antibody and the osteoclast inhibitor zoledronic acid increased bone mass and fracture resistance synergistically. However, anti-sclerostin antibody did not affect tumor burden

Indexed as

Adaptor Proteins, Signal TransducingAnimalsAntibodies, MonoclonalAntineoplastic AgentsApoptosisBone DiseasesBone Morphogenetic ProteinsBortezomibGenetic MarkersHumansMiceMultiple MyelomaOsteocytesOsteogenesisOsteolysisZoledronic AcidAdaptor Proteins, Signal TransducingAntibodies, MonoclonalAntineoplastic AgentsBone Morphogenetic ProteinsBortezomibGenetic MarkersromosozumabSOST protein, humanZoledronic Acidbone diseaseimmunotherapymultiple myelomaosteocytessclerostin

Identifiers

PMID30410490
PMCPMC6209728
OpenAlexW2898425271

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.